Author | Rachel Narozniak, MA | OncLive

Author | Rachel Narozniak, MA


SOLAR-1 OS Data Suggests Benefit in HR+/HER2– PIK3CA-Mutant Breast Cancer Subgroups

September 19, 2020

Although the SOLAR-1 trial did not cross the prespecified O’Brien-Fleming efficacy boundary in postmenopausal patients with PIK3CA-mutant, hormone receptor–positive, HER2-negative advanced breast cancer, alpelisib and fulvestrant nevertheless prolonged the median OS.

PD-L1 Status Guides TIL activity in NeoTRIPaPDL1

September 19, 2020

Although atezolizumab did not improve pathological complete response when added to carboplatin and nab-paclitaxel, the immunotherapy increased the pCR by 10% or more in “immune-rich” groups with high-risk and locally advanced triple-negative breast cancer, and also turned PD-L1 negative tumors positive in most immunotherapy-treated patients.

Investigator Looks to Novel Therapy to Advance TP53-Mutant MDS Landscape

September 17, 2020

David P. Steensma, MD, discusses the importance of evaluating eprenetapopt in the pivotal phase 3 study, the agent’s potential role in the MDS landscape, and some of the questions that remain in this setting.